Health savings services provider $HQY's 1Q17 revenue increased by 47% versus 1Q16. Adjusted EBITDA grew 66% to $18MM and adjusted EBITDA margins reached a company record of 41%. Gross profit for the quarter was $27.7MM versus $17.9MM in 1Q16.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.
$UBSI completed its acquisition of Cardinal Financial Corp. This transaction marks the 31st acquisition United has completed under the current administration and the tenth acquisition in the D.C. Metro region.
$HCI BoD has approved the termination of its shareholder rights plan, commonly referred to as a “poison pill,” by amending the associated rights agreement to accelerate the expiration date to April 18, 2017. Shareholders are not required to take any action as a result of this termination.
$MRK announced new phase 2 data on investigational triple combination therapy MK-3682B for chronic hepatitis C virus (HCV) genotype (GT) 1 infection for whom treatment with approved direct-acting antiviral regimens had failed.
$LLY announced phase 3 Monarch 3 breast cancer study of abemaciclib demonstrated superior progression-free survival at interim analysis. The trial met its primary endpoint of demonstrating statistically significant improvement in progression-free survival.